We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

2 hedge funds and large institutions have $12.8K invested in Windtree Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0% → 0% (+0%)

87% less funds holding

Funds holding: 15 → 2 (-13)

93% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 14

95% less capital invested

Capital invested by funds: $279K → $12.8K (-$266K)

Holders
2
Holders Change
-13
Holders Change %
-86.67%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$6.7K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$57K
2
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$36.1K
3
PAM
PVG Asset Management
Colorado
-$31.8K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$28.6K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$26K

WINT Hedge Fund Activity: Q1 2023 in Review

2 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q1 2023, worth a combined $12.8K — down 95% from $279K a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of WINT and 1 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $6.7K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $57K sold.

  • 2 institutional investors held Windtree Therapeutics (WINT) as of Q1 2023, down from 15 in Q4 2022.
  • Funds reported $12.8K of Windtree Therapeutics stock for Q1 2023, down 95% quarter-over-quarter.
  • 1 fund opened new Windtree Therapeutics positions in Q1 2023 and 14 closed out, a net change of -13 holders.
  • The largest Windtree Therapeutics buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $6.7K added.
  • The largest Windtree Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $57K sold.

Based on aggregated 13F filings for Q1 2023.